MARKET COMPOSITE
NTRA - Natera Inc8:00:00 PM 9/29/2023
Price
$44.25
-1.07 (-2.36%)
Natera is a genetic testing company that operates a CLIA-certified laboratory in San Carlos, California. The company specializes in analyzing microscopic quantities of DNA for reproductive health indications to provide preconception and prenatal genetic testing services to OBGYN physicians and in vitro fertilization centers. In early 2013, the company launched Panorama, a non-invasive prenatal test for pregnant women that screens for the most common chromosomal anomalies in a fetus as early as nine weeks of gestation. Other services include tests for preimplantation genetic diagnosis and miscarriage testing to determine the cause of the loss of the pregnancy. A non-invasive paternity test based on Natera’s technology, was brought to market in August 2011 through a partnership with DNA Diagnostics Center , which holds a license to the technology in the United States.
Financials
Quarterly financials
(USD)Dec 2022Q/Q
Revenue217.3MM+3%
Operating Income-141.8MM+19%
Operating Expenses359MM-
Net Income-142.6MM+17%
R&D87.9MM+34%
G&A143.8MM-3%
Interest Expense2.8MM+18%
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    AUSTIN, Texas, September 18, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced three appointments within its senior leadership team, effective immediately.

    An in-depth look at Natera Inc's valuation and financial performance

    AUSTIN, Texas, September 14, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study as part of the I-SPY 2 trial, sponsored and operated by Quantum Leap Healthcare Collaborative, that will use Signatera, Natera’s personalized and tumor-informed molecular residual disease (MRD) test, to monitor response to neoadjuvant therapy in breast cancer patients across all subtypes.

    AUSTIN, Texas, September 07, 2023--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 4,550,000 shares of its common stock at a price to the public of $55.00 per share. Closing of the offering is expected to occur on September 11, 2023, subject to customary closing conditions. In addition, Natera has granted the underwriters a 30-day option to purchase up to an additional 682,500 shares of its common s

    AUSTIN, Texas, September 06, 2023--Natera, Inc. (Nasdaq: NTRA) ("Natera"), a global leader in cell-free DNA (cfDNA) testing, today announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an additional $37,500,000 of shares of its common stock at the public offering price less the underwriting discounts and commissions. The offering is subject to market and o

    Fred Alger Management, an investment management company, released its “Alger Spectra Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here. In the second quarter, the fund outperformed the Russell 3000 Growth Index which returned 12.47%. Healthcare and Industrial sectors were the contributors to the fund’s relative performance in the quarter, […]

    AUSTIN, Texas, September 01, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the following investor conferences:

    In this piece, we will take a look at Stanley Druckenmiller’s 13F portfolio and its top 15 stock picks. If you want to skip our introduction to the billionaire hedge fund boss and the stock market in general, then take a look at Stanley Druckenmiller 13F Portfolio: Top 5 Stocks. The high interest rate environment […]

    AUSTIN, Texas, August 16, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received confirmation that its Prospera Lung donor-derived cfDNA (dd-cfDNA) transplant assessment test has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX).

    One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Natera just hit that mark, with a jump from 79 to 82 Friday. IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score.